Windlas Biotech Limited
₹1,129.25
-0.01%
Delayed · cached 15 min
Fair value analysis
WINDLAS
Windlas Biotech Limited
₹1,129.40
Close used for this calculation
₹764.40Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
53/100
Quality radar
Consensus fair value
₹764.40
Above FV▼ -32.3% against the close used
Model range ₹355.99 – ₹1,201.79
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹355.99Fair value₹764.40Bull₹1,201.79
FairClose
52-week traded range
52W low ₹705.7552W high ₹1,154.75
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Windlas Biotech Limited closed at ₹1,129.40, 47.7% above the consensus fair value of ₹764.40 drawn from 9 valuation models.
Financial DNA score 53/100 — Good. P/E of 35.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹355.99
-68.5%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹446.16
-60.5%
√(22.5 × EPS × BVPS)
EPS=31.49, BVPS=280.95 · outside Graham range (P/E 35.1, P/B 4) — asset-light, treat as a rough floor
Graham Formula
₹1,201.79
+6.4%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=16.3%, FD=7%
P/E Fair Value
₹1,124.19
-0.5%
EPS × 35.7x (sector P/E)
EPS=31.49, Sector P/E=35.7x
Peter Lynch (PEG)
₹513.29
-54.6%
EPS × Growth% (PEG = 1 is fair)
EPS=31.49, g=16.3%
EV/EBITDA
₹1,169.63
+3.6%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=1.36B
Book Value (P/B)
₹435.47
-61.4%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=280.95, ROE=12.2%, g=6%, r=10%
Reverse DCF
₹1,129.40
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 15% | Historical: 16.3%
Margin of Safety
₹586.52
-48.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=782.03, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.